| 2025-12-31 | Stryker Corporation | $3,243 | Debt forgiveness | Cash or cash equivalent | | | 2025 |
| 2025-12-31 | Stryker Corporation | $170 | Debt forgiveness | Cash or cash equivalent | | | 2025 |
| 2025-12-31 | BIOTRONIK INC. | $53 | Debt forgiveness | Cash or cash equivalent | | | 2025 |
| 2025-12-31 | Stryker Corporation | $21 | Debt forgiveness | Cash or cash equivalent | | | 2025 |
| 2025-12-15 | Janssen Research & Development, LLC | $6,237 | Research payment | Cash or cash equivalent | | A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS) | 2025 |
| 2025-11-21 | Janssen Research & Development, LLC | $4,053 | Research payment | Cash or cash equivalent | | A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS) | 2025 |
| 2025-11-17 | Novartis Pharmaceuticals Corporation | $1,869 | Research payment | Cash or cash equivalent | LEQVIO Drug, Cardiology/Vascular Diseases | A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Majo | 2025 |
| 2025-10-27 | Novartis Pharmaceuticals Corporation | $20 | Research payment | In-kind items and services | LEQVIO Drug, Cardiology/Vascular Diseases | A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Majo | 2025 |
| 2025-10-22 | Janssen Research & Development, LLC | $3,900 | Research payment | Cash or cash equivalent | | A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS) | 2025 |
| 2025-10-09 | Humacyte Global, Inc. | $2,726 | Research payment | Cash or cash equivalent | Symvess Biological, Extremity Arterial Injury | To Compare the Efficacy and Safety of the ATEV With AVF in Female Patients With End-Stage Renal Disease Requiring Hemodi | 2025 |
| 2025-10-08 | Humacyte Global, Inc. | $1,308 | Research payment | Cash or cash equivalent | Symvess Biological, Extremity Arterial Injury | To Compare the Efficacy and Safety of the ATEV With AVF in Female Patients With End-Stage Renal Disease Requiring Hemodi | 2025 |
| 2025-09-23 | Baxter Healthcare | $73 | Debt forgiveness | In-kind items and services | | | 2025 |
| 2025-09-19 | Janssen Research & Development, LLC | $4,785 | Research payment | Cash or cash equivalent | | A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS) | 2025 |
| 2025-09-10 | PFIZER INC. | $1,963 | Research payment | Cash or cash equivalent | TIVDAK Biological, ONCOLOGY | A RANDOMIZED OPENLABEL PHASE 3 TRIAL OF TISOTUMAB VEDOTIN VS INVESTIGATORS CHOICE CHEMOTHERAPY IN SECOND OR THIRDLINE RE | 2025 |
| 2025-08-25 | Janssen Research & Development, LLC | $3,900 | Research payment | Cash or cash equivalent | | A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS) | 2025 |
| 2025-08-25 | Humacyte Global, Inc. | $1,581 | Research payment | Cash or cash equivalent | Symvess Biological, Extremity Arterial Injury | To Compare the Efficacy and Safety of the ATEV With AVF in Female Patients With End-Stage Renal Disease Requiring Hemodi | 2025 |
| 2025-07-25 | Novartis Pharmaceuticals Corporation | $12,524 | Research payment | Cash or cash equivalent | | A Phase 3, Randomized, Double-blind, Placebo-controlled Study of BION-1301 in Adults With IgA Nephropathy (The BEYOND St | 2025 |
| 2025-07-14 | Janssen Research & Development, LLC | $6,895 | Research payment | Cash or cash equivalent | | A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS) | 2025 |
| 2025-07-08 | Gilead Sciences, Inc. | $92,823 | Grant | Cash or cash equivalent | | | 2025 |
| 2025-07-08 | Boston Scientific Corporation | $14,172 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product_CRM | LUX-DX TRENDS | 2025 |
| 2025-06-30 | Zimmer Biomet Holdings, Inc. | $121 | Debt forgiveness | Cash or cash equivalent | | | 2025 |
| 2025-06-25 | Janssen Research & Development, LLC | $1,957 | Research payment | Cash or cash equivalent | | A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS) | 2025 |
| 2025-06-20 | Janssen Research & Development, LLC | $4,868 | Research payment | Cash or cash equivalent | | A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS) | 2025 |
| 2025-06-18 | Abbott Laboratories | $2,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | JETI PERIPHERAL CATHETER Device, Vascular | | 2025 |
| 2025-06-17 | Boston Scientific Corporation | $10,250 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product_CRM | ADVENT PAS | 2025 |
| 2025-06-17 | Volta Medical Inc | $4,250 | Research payment | Cash or cash equivalent | AF-Xplorer Device, Devices | COMPANION AI | 2025 |
| 2025-05-27 | Gilead Sciences, Inc. | $61,039 | Grant | Cash or cash equivalent | | | 2025 |
| 2025-05-27 | Gilead Sciences, Inc. | $10,100 | Grant | Cash or cash equivalent | | | 2025 |
| 2025-05-23 | Janssen Research & Development, LLC | $1,524 | Research payment | Cash or cash equivalent | | A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS) | 2025 |
| 2025-05-22 | Penumbra, Inc. | $1,000 | Grant | Cash or cash equivalent | | | 2025 |
| 2025-05-15 | BIOTRONIK INC. | $2,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | | | 2025 |
| 2025-05-08 | Edwards Lifesciences Corporation | $2,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | | | 2025 |
| 2025-05-08 | Stryker Corporation | $500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | VSP SYSTEM, VSP CRANIAL Device, CRANIOMAXILLOFACIAL | | 2025 |
| 2025-05-08 | Stryker Corporation | $500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | DURACON Device, KNEES | | 2025 |
| 2025-05-07 | Boston Scientific Corporation | $2,500 | Grant | In-kind items and services | General - EP Device, General - EP_EP | | 2025 |
| 2025-05-02 | Novartis Pharmaceuticals Corporation | $2,018 | Research payment | Cash or cash equivalent | | A Phase 3, Randomized, Double-blind, Placebo-controlled Study of BION-1301 in Adults With IgA Nephropathy (The BEYOND St | 2025 |
| 2025-04-23 | Janssen Research & Development, LLC | $3,226 | Research payment | Cash or cash equivalent | | A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS) | 2025 |
| 2025-03-25 | Biosense Webster, Inc. | $2,500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | CARTO 3 Device, Cardiology | | 2025 |
| 2025-03-17 | Siemens Medical Solutions USA, Inc. | $5,400 | Research payment | Cash or cash equivalent | ADVIA Centaur XP Analyzer Device, DX - Diagnostics incl. all products and services | PE OUS STUDY | 2025 |
| 2025-03-17 | Janssen Research & Development, LLC | $3,811 | Research payment | Cash or cash equivalent | | A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS) | 2025 |
| 2025-03-14 | Siemens Medical Solutions USA, Inc. | $8,903 | Research payment | Cash or cash equivalent | ADVIA Centaur XP Analyzer Device, DX - Diagnostics incl. all products and services | PE OUS STUDY | 2025 |
| 2025-03-14 | AstraZeneca Pharmaceuticals LP | $2,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | | | 2025 |
| 2025-03-12 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | | | 2025 |
| 2025-03-06 | E.R. Squibb & Sons, L.L.C. | $2,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | CAMZYOS Drug, Cardiovascular | | 2025 |
| 2025-02-27 | Novartis Pharmaceuticals Corporation | $12,454 | Research payment | Cash or cash equivalent | LEQVIO Drug, Cardiology/Vascular Diseases | A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Majo | 2025 |
| 2025-02-25 | SUVON SURGICAL LLC | $3,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | | | 2025 |
| 2025-02-24 | Janssen Research & Development, LLC | $1,616 | Research payment | Cash or cash equivalent | | A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS) | 2025 |
| 2025-02-21 | ENDOTRONIX, INC. | $16,683 | Research payment | Cash or cash equivalent | CORDELLA PULMONARY ARTERY PRESSURE SENSOR Device, HEART FAILURE | PROACTIVE-HF | 2025 |
| 2025-01-28 | Boston Scientific Corporation | $1,050 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product_CRM | LUX-DX TRENDS | 2025 |
| 2025-01-22 | Janssen Research & Development, LLC | $9,424 | Research payment | Cash or cash equivalent | | A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome (LIBREXIA-ACS) | 2025 |
Comments